Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen
Rm the safety and efficacy profile of ABP 501. In a phase I human pharmacokinetic study, ABP 501 has been shown to be similar to adalimumab (US) and adalimumab (EU) [26, 27]. Clinical studies designed to assess the similarity of ABP 501 relative to the adalimumab reference product for the treatment of moderate to severe plaque psoriasis [28, 29] and moderate to severe rheumatoid arthritis [30, 31]
Rm the safety and efficacy profile of ABP 501. In a phase I human pharmacokinetic study, ABP 501 has been shown to be similar to adalimumab (US) and adalimumab (EU) [26, 27]. Clinical studies designed to assess the similarity of ABP 501 relative to the adalimumab reference product for the treatment of moderate to severe plaque psoriasis [28, 29] and moderate to severe rheumatoid arthritis [30, 31]